Puma Biotechnology, Inc. (NASDAQ: PBYI) saw its shares touch a multiyear high on Tuesday after the firm reported a key approval by the U.S. Food and Drug Administration (FDA). Specifically, the agency approved Nerlynx…
Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted $1.83 in earnings per share (EPS) on $18.8 billion in revenue. The second quarter…
UnitedHealth's second-quarter earnings beat the consensus estimate for profits and met the estimate for revenues. Investors reacted indifferently to the report.
Sienna Biopharmaceuticals filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 4.33 million shares in the range of…
Medical technology company Apollo Endosurgery saw its shares slide on Friday after the company announced terms of its secondary offering.
The June 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Ocular Therapeutix shares were absolutely crushed on Wednesday after the company received less than favorable news from the FDA regarding its Dextenza in the treatment of ocular pain following ophthalmic surgery.
PetIQ intends to price more than 5 million shares in the range of $14 to $16 apiece in an initial public offering valued up to more than $104 million.
The biotech industry has made a splash in 2017, outperforming practically all the broad markets. With this incredible display, it's no wonder that investor interest in this particular industry has grown, and one analyst…
Shares of Arena Pharmaceuticals saw an incredible gain early Tuesday after the company reported positive results from its mid-stage trial in patients with pulmonary arterial hypertension.
Despite the concerns over the struggles of politicians to craft a new health care plan for the United States, the health care sector, and many of its subsectors, have had an outstanding first half…
Kala Pharmaceuticals intends to price 6 million shares in the range of $14 to $16 apiece in an initial public offering valued up to more than $110 million.
In an incredible move on Friday, the FDA approved Endari for the treatment of patients age five and older with sickle cell disease to reduce severe complications that are common with the blood disorder.
Conatus Pharmaceuticals saw its shares make a handy gain on Friday after the firm announced an exclusive license agreement with Novartis.
